Biosilu Healthcare AG (1YA)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Biosilu Healthcare AG (1YA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8011872
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月13日
◆ページ数:19
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Biosilu Healthcare AG (Biosilu Healthcare), formerly Amp Biosimilars AG is a life science company that develops and commercializes biopharmaceuticals. The company’s product pipeline comprises biosimilar development projects on immune disorders and cancer. It offers products in therapeutic areas of infectious diseases, fertility, tumor indications and other rare diseases. Biosilu Healthcare also provides advises for Asian biopharmaceutical companies and investors in outreach to Western markets, partners and investment opportunities. The company develops products with a clinical-proof-of-concept in areas of high medical needs in Asia. It partners with western biopharmaceutical companies. The company operates in Germany and China. Biosilu Healthcare is headquartered in Frankfurt, Germany.

Biosilu Healthcare AG (1YA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Biosilu Healthcare AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Biosilu Healthcare AG, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Biosilu Healthcare AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Biosilu Healthcare AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Biosilu Healthcare AG, Medical Devices Deals, 2011 to YTD 2017 9
Biosilu Healthcare AG, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Biosilu Healthcare AG, Pharmaceuticals & Healthcare, Deal Details 11
Licensing Agreements 11
amp biosimilars Enters into Licensing Agreement for ABY-021 Biosimilar 11
amp biosimilars Enters into Licensing Agreement for Biosimilar 12
Equity Offering 13
Biosilu Healthcare Raises USD0.5 Million in Private Placement of Shares 13
amp biosimilars Raises USD28.67 Million in IPO 14
Biosilu Healthcare AG – Key Competitors 15
Biosilu Healthcare AG – Key Employees 16
Biosilu Healthcare AG – Locations And Subsidiaries 17
Head Office 17
Recent Developments 18
Corporate Communications 18
Jun 28, 2016: amp biosimilars announces Klaus K. Wilgenbus as new CEO 18
Appendix 19
Methodology 19
About GlobalData 19
Contact Us 19
Disclaimer 19

List of Tables
Biosilu Healthcare AG, Pharmaceuticals & Healthcare, Key Facts 2
Biosilu Healthcare AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Biosilu Healthcare AG, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Biosilu Healthcare AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Biosilu Healthcare AG, Deals By Therapy Area, 2011 to YTD 2017 8
Biosilu Healthcare AG, Medical Devices Deals, 2011 to YTD 2017 9
Biosilu Healthcare AG, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
amp biosimilars Enters into Licensing Agreement for ABY-021 Biosimilar 11
amp biosimilars Enters into Licensing Agreement for Biosimilar 12
Biosilu Healthcare Raises USD0.5 Million in Private Placement of Shares 13
amp biosimilars Raises USD28.67 Million in IPO 14
Biosilu Healthcare AG, Key Competitors 15
Biosilu Healthcare AG, Key Employees 16

★海外企業調査レポート[Biosilu Healthcare AG (1YA)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Demant AS (DEMANT):企業の財務・戦略的SWOT分析
    Demant AS (DEMANT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Norfolk Southern Corporation:企業の戦略・SWOT・財務分析
    Norfolk Southern Corporation - Strategy, SWOT and Corporate Finance Report Summary Norfolk Southern Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • McCarthy & Stone Plc:企業の戦略・SWOT・財務情報
    McCarthy & Stone Plc - Strategy, SWOT and Corporate Finance Report Summary McCarthy & Stone Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Titan Cement Company Sa
    Titan Cement Company Sa - Strategy, SWOT and Corporate Finance Report Summary Titan Cement Company Sa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Utah Medical Products Inc (UTMD):企業の財務・戦略的SWOT分析
    Summary Utah Medical Products Inc (Utah Medical) is a medical device company that offers disposable and reusable products. The company offers blood pressure monitoring and blood management, gynecology, urology and electrosurgery, perinatology, respiratory and OEM products. Its blood pressure monitor …
  • Vitasoy International Holdings Ltd (0345):企業の財務・戦略的SWOT分析
    Vitasoy International Holdings Ltd (0345) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • RespireRx Pharmaceuticals Inc (RSPI):製薬・医療:M&Aディール及び事業提携情報
    Summary RespireRx Pharmaceuticals Inc (RespireRx), formerly Cortex Pharmaceuticals, Inc., focuses on the discovery, development and commercialization of innovative products for the treatment of various respiratory disorders. It has two drug platforms, each with a clinical stage compound directed at …
  • Capri Holdings Ltd:企業の戦略・SWOT・財務分析
    Capri Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Capri Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Mount Tam Biotechnologies Inc (MNTM):製薬・医療:M&Aディール及び事業提携情報
    Summary Mount Tam Biotechnologies Inc (Mount Tam Biotechnologies), a subsidiary of TabacaleraYsidron Inc is a provider of pharmaceutical products that offers development and commercialization of medical compounds for autoimmune diseases. The company’s lead product candidate TAM-0, a rapamycin analog …
  • Concord New Energy Group Ltd (182):企業の財務・戦略的SWOT分析
    Concord New Energy Group Ltd (182) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Warner Music Group Corp.:企業の戦略的SWOT分析
    Warner Music Group Corp. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Oasis Diagnostics Corp:企業の製品パイプライン分析2018
    Summary Oasis Diagnostics Corp (Oasis Diagnostics) is a medical device company that develops and commercializes tools for non-invasive diagnosis and detection of diseases. The company's products include saliva DNA isolation kit, genomic kit and immunoassay products, among others. Its saliva DNA isol …
  • Obuv Rossii OOO (OBUV):企業の財務・戦略的SWOT分析
    Obuv Rossii OOO (OBUV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • KS Drilling Pte Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary KS Drilling Pte Ltd (KS Drilling) formerly known as Atlantic Oilfield Services Ltd a subsidiary of KS Energy Limited, is a drilling and rig management company that operates onshore and offshore drilling units. The company provides shallow water and onshore drilling services. It offers land r …
  • BTG Plc (BTG):製薬・医療:M&Aディール及び事業提携情報
    Summary BTG plc (BTG) develops, manufactures and sells medicines for acute care, cancer and vascular diseases. The company develops specialty drugs including antidotes for snake envenomation and toxicity related to medicines used for heart conditions and cancer; interventional vascular products for …
  • Dairy Farm International Holdings Limited:戦略・SWOT・企業財務分析
    Dairy Farm International Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Dairy Farm International Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …
  • Al Arrab Contracting Company:企業の戦略的SWOT分析
    Al Arrab Contracting Company - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Candover Investments plc (CDI):企業の財務・戦略的SWOT分析
    Candover Investments plc (CDI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Barra Resources Limited:企業の戦略・SWOT・財務分析
    Barra Resources Limited - Strategy, SWOT and Corporate Finance Report Summary Barra Resources Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Aura Light International AB:企業の戦略的SWOT分析
    Aura Light International AB - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆